Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05995249 · ClinicalTrials.gov registry record · Phase 1
A Study of the Interaction of TAK-279 With Substances That Have an Impact on Metabolism in Healthy Adults
A Phase 1 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 1
- Development phase
- 172
- Enrollment target
NCT05995249 is a Phase 1 study that has completed, run by Takeda. The registered enrollment target is 172 participants.
The verdict
NCT05995249, a Phase 1 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 172 participants
- Enrollment target
Study Summary
The main aim of this study is to find out how the body of a healthy adult processes TAK-279 (pharmacokinetics) when substances that either hinder or help the human metabolism such as erythromycin, phenytoin and efavirenz are given along with TAK-279. Other aim is to learn about side effects and how well it is tolerated when TAK-279 is given alone and together with substances that impact human metabolism. The participants will need to stay at the clinic for up to 26 days.
Interventions
- DRUG TAK-279
- DRUG Erythromycin
- DRUG Efavirenz
- DRUG Phenytoin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 172 participants |
| Start Date | 2023-08-11 |
| Est. Completion | 2023-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05995249
The ClinicalTrials.gov registry entry for NCT05995249 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 172 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which TAK-279 is the first listed.
NCT05995249 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05995249 about?
NCT05995249 is a clinical study titled "A Study of the Interaction of TAK-279 With Substances That Have an Impact on Metabolism in Healthy Adults". The main aim of this study is to find out how the body of a healthy adult processes TAK-279 (pharmacokinetics) when substances that either hinder or help the human metabolism such as erythromycin, phenytoin and efavirenz are given along with TAK-279. Other aim is to learn about side effects and how ...
What is the current status of trial NCT05995249?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 172 participants. The study started on 2023-08-11. Estimated completion is 2023-12-31.
What interventions are being tested in trial NCT05995249?
The interventions under investigation include: TAK-279 (DRUG), Erythromycin (DRUG), Efavirenz (DRUG), Phenytoin (DRUG).
Who is sponsoring clinical trial NCT05995249?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.